Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Karyopharm raises $10mm through Series A2 round

Executive Summary

Karyopharm Therapeutics Inc. (cancer, dermatology, inflammatory, and viral disease drug development) raised $10mm through its Series A2 round led by original Series A investor Chione Ltd. Proceeds will be used to advance the company's first oral selective inhibitor of nuclear transport (SINE) candidate into Phase I trials for hematologic cancers and solid tumors. Karyopharm was formed in 2008 and raised $20mm in its Series A exactly one year ago.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies

Advertisement
UsernamePublicRestriction

Register